U055 Practical Considerations for Systemic Treatment of Atopic Dermatitis in Adults
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
The therapeutic armamentarium for moderate-to-severe atopic dermatitis is expanding. Conventional immunomodulators (methotrexate, cyclosporine), biologics (dupilumab, tralokinumab), and JAK inhibitors (abrocitinib, upadacitinib) are available, with more on the way. These exciting developments will improve patients’ quality of life, but make shared decision-making more complex. In this session, we will review practical aspects of systemic treatments for adult atopic dermatitis, including the latest relative efficacy evidence. We will discuss common and rare adverse events associated with these medications and how to monitor for and manage them. We will discuss patient characteristics that can guide which medication to choose for individual patients.
LEARNING OBJECTIVES
Compare the relative efficacy and safety of available systemic treatment options for adult atopic dermatitis, including conventional immunomodulators, biologics and JAK inhibitors.
Recognize adverse events associated with systemic treatments for atopic dermatitis and how to monitor for and manage them.
Differentiate the advantages and disadvantages of available systemic treatment options for atopic dermatitis in special populations of adults, including older adults and adults with comorbidities.
SCHEDULE
12:00 PM
Comparative efficacy of systemic treatments for atopic dermatitis
Aaron Mark Drucker, MD, FAAD
12:15 PM
Using systemic treatments for atopic dermatitis safely – monitoring and recognizing adverse events
Eric Lawrence Simpson, MD, FAAD
12:30 PM
Considerations when using systemic treatments in special populations of adults with atopic dermatitis
Katrina Abuabara, MD, FAAD
12:45 PM
Q&A
SPEAKERS
Katrina Abuabara, MD, FAAD
Aaron Mark Drucker, MD, FAAD
Eric Lawrence Simpson, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Katrina Abuabara, MD, FAAD
Amgen – Consultant (1099 relationship)(Fees); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Astria Therapeutics – Consultant (1099 relationship)(Fees); Cedar Healthcare – Stockholder(Stock); Cosmetique – Investigator(Grants/Research Funding); Healthpilot – Stockholder(Stock Options); Incyte – Consultant (1099 relationship)(Fees); Medidata – Consultant (1099 relationship)(Fees); Nektar Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Investigator(Grants/Research Funding); Picwell Inc. – Board of Directors(Stock); Sanofi – Consultant (1099 relationship)(Fees); TARGET Pharma – Advisory Board(Fees);
Aaron Mark Drucker, MD, FAAD
No financial relationships exist with ineligible companies.
Eric Lawrence Simpson, MD, FAAD
AbbVie – Consultant(Fees), Investigator(Grants/Research Funding); Acrotech Biopharma Inc – Investigator(Grants/Research Funding); Amgen – Consultant(Fees), Investigator(Grants/Research Funding); Arcutis Biotherapeutics – Consultant(Fees); Arcutis, Inc. – Investigator(Grants/Research Funding); Areteia Therapeutics – Consultant (1099 relationship)(Fees); ASLAN – Consultant(Fees); ASLAN Pharmaceuticals – Investigator(Grants/Research Funding); Astria Therapeutics – Consultant (1099 relationship)(Fees); Bristol-Myers Squibb – Consultant(Fees); Castle Biosciences – Investigator(Grants/Research Funding); CorEvitas – Consultant(Fees), Investigator(Grants/Research Funding); Corvus Pharmaceuticals – Consultant (1099 relationship)(Fees); Demira – Consultant(Fees); Dermavant – Investigator(Grants/Research Funding); Dermavant Sciences, Inc. – Investigator(Grants/Research Funding); Dermira – Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant(Fees), Investigator(Grants/Research Funding); Evelo Biosciences, Inc. – Consultant(Fees); FIDE – Speaker/Faculty Education(Fees); Forte Biosciences – Consultant(Fees); Galderma Laboratories, LP – Consultant (1099 relationship)(Fees); Gilead Sciences, Inc – Consultant (1099 relationship)(Fees); GlaxoSmithKline – Consultant(Fees); Impetus Healthcare – Consultant (1099 relationship)(Fees); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); Innovaderm Research Inc. – Consultant (1099 relationship)(Fees); Janssen Research & Development, LLC – Consultant(Fees); Johnson & Johnson Pharmaceutical Research & Development – Consultant(Fees); Kymab – Investigator(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Leo Pharma Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Med Learning Group – Consultant(Fees); Merck – Advisory Board(Fees); National Jewish Health – Investigator(Grants/Research Funding); Novartis – Investigator(Grants/Research Funding); NUMAB Therapeutics AG – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Physicians World LLC – Consultant(Fees); Prime Education – Speaker/Faculty Education(Honoraria); Recludix Pharma – Consultant (1099 relationship)(Fees); Regeneron – Consultant(Fees), Investigator(Grants/Research Funding); Roche Products Ltd – Consultant (1099 relationship)(Fees); Roivant Sciences – Consultant(Fees), Consultant (1099 relationship)(Fees); Sanofi – Investigator(Grants/Research Funding); Sanofi Genzyme – Consultant(Fees), Investigator(Grants/Research Funding); SITRYX – Consultant (1099 relationship)(Fees); Target RWE – Investigator(Grants/Research Funding); Tioga Pharmaceuticals, Inc. – Investigator(Grants/Research Funding); Trevi Therapeutics – Consultant(Fees); Valeant Pharmaceuticals International – Consultant(Fees); Vanda Pharmaceuticals Inc. – Investigator(Grants/Research Funding); Veriskin – Investigator(Grants/Research Funding); Vindico Medical Education – Speaker/Faculty Education(Honoraria); WebMD – Consultant(Fees);